Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
Haemophilia, 2019 Emicizumab is a bispecific monoclonal antibody that mimics factor VIII (FVIII) by binding to factors IXa and X to promote hemostasis in haemophilia A (HA) and HA with inhibitors (HA‐I). As emicizumab differs biochemically from FVIII, there is interest in
Patrick T. Ebbert +3 more
semanticscholar +1 more source
Human parvovirus B19 and blood product safety. A tale of twenty years of improvements [PDF]
, 2015 Parvovirus B19 (B19V), long known to be the causative agent of erythema infectiosum (fifth disease), is not a newly emerging agent. The aim of this review is to analyse the role played by this virus in compromising safety in transfusion medicine and the ...
Calizzani, Gabriele +7 more
core +1 more source
The inhibitors – a challenge for the management of patients with hereditary haemophilia A
Romanian Journal of Internal Medicine, 2018 Introduction. Our research strategy was aimed at evaluating the possible implication of the type of factor VIII product administered as substitution treatment to haemophilia A patients in the occurrence of inhibitors and their consequences on the ...
Mihăilă Romeo-Gabriel
doaj +1 more source
Acquired haemophilia A: a case report
Studia Medyczne, 2017 Acquired haemophilia A is rare, autoimmune bleeding disorder caused by the production of autoantibodies against coagulation factor VIII (FVIII). The disorder affects 1.5 people per 1 million population a year, particularly the elderly.
Adam Stemplewski +3 more
doaj +1 more source
Factor VIII products: key aspects of development, clinical research and use (part 2)
Биопрепараты: Профилактика, диагностика, лечение, 2021 Continuous replacement therapy with clotting factor products can lead to serious complications in haemophilia A patients. One of potential reasons of such complications is an undesirable immune response to a blood clotting factor VIII (FVIII) product ...
Zh. I. Avdeeva +4 more
doaj +1 more source
Inhibitor development in non-severe haemophilia across Europe [PDF]
, 2015 Evidence about inhibitor formation in non-severe haemophilia and the potential role for clotting factor concentrate type is scant. It was the aim of this study to report inhibitor development in non-severe haemophilia patients enrolled in the European ...
Calizzani, Gabriele +13 more
core +3 more sources
On a break with the X: the role of repair of double-stranded DNA breaks in X-linked disease [PDF]
, 2012 The problem of managing free reactive DNA ends in eukaryotic cells has resulted in the development of a number of mechanisms in order to ensure that free ends are rendered non-reactive, or that the double-strand DNA breaks generating the free ends are ...
Cecceroni, Lucia +2 more
core +3 more sources
Endodontic Management of a Haemophilic Patient- A Clinical Perspective [PDF]
Journal of Clinical and Diagnostic Research, 2014 Haemophilia and other bleeding disorders remain an enigma to the dentists world over. They not only challenge the skills of dental specialists but also raise the question of how these individuals should be managed emotionally as well as psychologically.
Pooja Gupta Dudeja +3 more
doaj +1 more source
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
Haemophilia, 2019 As a result of the new treatment paradigm that the haemophilia community will face with the availability of novel (non‐factor) therapies, an updated consensus on ITI recommendations and inhibitor management strategies is needed.
M. Carcao +8 more
semanticscholar +1 more source
PTH6: PATIENTS' PERCEPTIONS OF THE OUTCOMES OF TREATMENT WITH TOPICAL NSAIDS, RUBIFACIANTS AND ORAL PAIN REMEDIES. A PROSPECTIVE STUDY OF MEDICINES AVAILABLE THROUGH COMMUNITY PHARMACIES [PDF]
, 1999 Obesity is a major health concern not only in the general population but also in patients with haemophilia. Little is known about the consequences of obesity for haemophilia patients.
Biere-Rafi, S. +5 more
core +1 more source